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Trends in the Risk for Coronary Heart
Disease Among Adults With Diagnosed
Diabetes in the U.S.
Findings from the National Health and Nutrition Examination Survey,
1999–2008
EARL S. FORD, MD, MPH
OBJECTIVE—Coronary heart disease (CHD) isa major cause of mortality among people with
diabetes. The objective of this study was to examine the trend in an estimated 10-year risk for
developing CHD among adults with diagnosed diabetes in the U.S.
RESEARCH DESIGN AND METHODS—Data from 1,977 adults, aged 30–79 years,
with diagnosed diabetes who participated in the National Health and Nutrition Examination
Survey from 1999–2000 to 2007–2008 were used. Estimated risk was calculated using risk
prediction algorithms from the UK Prospective Diabetes Study (UKPDS), the Atherosclerosis
Risk in Communities study, and the Framingham Heart Study.
RESULTS—Signiﬁcant improvementsin mean HbA1cconcentrations, systolicbloodpressure,
and the ratio of total cholesterol to HDL cholesterol occurred. No signiﬁcant linear trend for
current smoking status was observed. The estimated UKPDS 10-year risk for CHD was 21.1% in
1999–2000 and 16.4% in 2007–2008 (Plinear trend , 0.001). The risk decreased signiﬁcantly
among men, women, whites, African Americans, and Mexican Americans.
CONCLUSIONS—The estimated 10-year risk for CHD among adults with diabetes has im-
proved signiﬁcantly from 1999–2000 to 2007–2008. Sustained efforts in improving risk factors
should further beneﬁt the cardiovascular health of people with diabetes.
Diabetes Care 34:1337–1343, 2011
M
any people with diabetes will
die from cardiovascular disease.
Therefore, controlling the risk
factors for cardiovascular disease is of
the utmost importance in reducing the
risk for developing cardiovascular disease
in the diabetic population. In the U.S.,
important strides have been made in re-
ducing the impact of several key risk
factors for cardiovascular disease. Thus,
the prevalence of smoking has fallen sub-
stantially, and concentrations of total
cholesterol (TC) have decreased, but
blood pressure levels have moved less
consistently(1–3).Somedatasuggestthat
these trends in the general population
also have played out in the diabetic pop-
ulation (4). If so, the risk for developing
coronary heart disease (CHD) should
havedecreasedamong peoplewithdiabe-
tes. Therefore, the objective of this study
was to examine the trends in the 10-year
risk for CHD among adults with diag-
nosed diabetes in the U.S. from 1999 to
2008.
RESEARCH DESIGN AND
METHODS—This study included data
from the National Health and Nutrition
Examination Survey (NHANES) 1999–
2008 (5). During each consecutive 2-year
cycle, a national sample was recruited
using a multistage, stratiﬁed sampling de-
sign. The surveys were designed to pro-
duce results representative of the civilian,
noninstitutionalized U.S. population. Par-
ticipants were interviewed at home and
were invited to attend a mobile examina-
tioncenter,wheretheywereaskedtocom-
pleteadditionalquestionnaires,toundergo
various examinations, and to provide a
bloodsample.Thestudyreceivedapproval
from the National Center for Health Statis-
ticsResearchEthicsReviewBoard,andpar-
ticipants were asked to sign an informed
consent form. Details about the survey
can be found elsewhere (5).
Participants who responded afﬁrma-
tively to the question, “Have you ever
been told by a doctor or health profes-
sional that you have diabetes or sugar di-
abetes?” were considered to have been
diagnosed with diabetes. The UK Pro-
spective Diabetes Study (UKPDS) Risk
Engine incorporates the following vari-
ables: age at diagnosis of diabetes; sex;
race or ethnicity;smoking status; concen-
tration of HbA1c; systolic blood pressure;
and the ratio of the concentrations of TC-
to-HDL cholesterol (HDLC) (6). The
10-year probability of developing CHD
also was calculated using risk equations
generated from the Framingham Heart
Study (FHS) (7) and the Atherosclerosis
Risk in Communities (ARIC) study (8).
TheFHSriskequationsuseage,age
2,cat-
egories of concentrations of TC, categories
of concentrations of HDLC, categories of
bloodpressure,diabetesstatus,andsmok-
ing status. The ARIC study risk equations
incorporate age, age
2, race, categories of
concentrations of TC, categories of con-
centrations of HDLC, systolic blood pres-
sure, use of antihypertensive medications,
and current smoking status.
Participants with diagnosed diabetes
were asked about their age when they
were ﬁrst told by a doctor or other health
professional that they had diabetes. Partic-
ipants who had smoked at least 100 ciga-
rettes during their lifetime and currently
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Trends in CVD risk among diabetic adultswere smoking were designated as current
smokers. Concentrations of HbA1c were
measured using Primus Automated HPLC
Systems (models CLC330 and CLC385;
Primus, Kansas City, MO) during 1999–
2004 at the University of Missouri
(Columbia, MO) and using an A1C 2.2
Plus Glycohemoglobin Analyzer or an
A1C G7 HPLC Glycohemoglobin Ana-
lyzer during 2005–2008 (Tosoh Medics,
South San Francisco, CA) at the Fairview
University Medical Center. The average of
the last two measurements of blood pres-
sureforparticipantswhohadthreeorfour
measurements, the last measurement for
participants with only twomeasurements,
and the only measurement for partici-
pants who had one measurement were
used. Current use of antihypertensive
medications was based on self-report.
From 1999 to 2006, serum TC and HDLC
were measured enzymatically using a
Hitachi 704, 717, or 912 Analyzer (Roche
Diagnostics, Indianapolis, IN) at Johns
Hopkins University. During 2007–2008,
serum cholesterol and HDLC were mea-
suredenzymaticallyonaRocheModularP
Chemistry Analyzer (Roche Diagnostics)
at the University of Minnesota. Because
changes in the methodology to measure
HDLC were enacted during the study pe-
riod, studies were conducted to measure
the effect of those changes in methods on
concentrations, and corrections were
made as necessary. Corrected concentra-
tions were used in this study.
Risk estimates were calculated for
participants aged 30–79 years with diag-
noseddiabetesfortheUKPDSriskengine,
for participants aged 45–65 years for the
ARIC study risk engine, and for partici-
pants aged 30–74 years for the FHS risk
engine. Tests for linear trend were con-
ducted by using regression analyses, in
which survey cycle was used as a contin-
uous variable. For race or ethnic-speciﬁc
estimates, only results for the three major
groups (whites, African Americans, and
Mexican Americans) are shown. Hypo-
thetical estimates of 10-year UKPDS risk
for diabetic adults were calculated under
the following scenarios: 1) eliminate all
current smoking; 2) reduce the concen-
tration of HbA1c to 6.9% for those who
had a concentration of $7%; 3) reduce
systolic blood pressure to 129 mmHg
for those with a systolic blood pressure
$130 mmHg; 4)r e d u c eT Ct o1 9 9m g / d L
for those with a concentration of TC
$200 mg/dL and increase concentrations
of HDLC to 40 mg/dL for diabetic men
with a concentration ,40 mg/dL and to
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Ford50 mg/dL for diabetic women with a con-
centration ,50 mg/dL; and 5) all of the
above. SUDAAN (software for the statisti-
cal analysis of correlated data; Research
Triangle Institute, Research Triangle
Park, NC) was used for the analyses to
account for the complex sampling design,
and sampling weights were used to gener-
ate estimates.
RESULTS—A total of 2,296 partici-
pants, aged 30–79 years, diagnosed with
diabetes hadamedicalexamination.After
excluding participants with missing data
for the variables needed to calculate the
estimated risk, 1,977 participants were
included in the analyses (1,021 men and
956 women; 715 whites, 531 African
Americans, 527 Mexican Americans, and
204 of another race or ethnicity). No sig-
niﬁcant linear trend in age was noted (P =
0.250).
In the entire sample, there were no
signiﬁcant linear trends with respect to
the percentage of women, the percentage
of African Americans, and the percentage
of current smokers (Table 1). However,
declining trends were observed for con-
centrationsofHbA1c,meansystolicblood
pressure, TC, and the ratio of TC/HDLC.
With the exception of the percentage of
current smokers and mean systolic blood
pressure in men, the direction or signiﬁ-
cance of the trends of the UKPDS risk en-
gine variables among men and women
were similar.
The estimated UKPDS 10-year risk
for developing CHD decreased signiﬁ-
cantly in the total sample (regression
coefﬁcient = 20.63% per year, SE =
0.17, Plinear trend , 0.001) as well as in
men (regression coefﬁcient = 20.65%
per year, SE = 0.22, Plinear trend = 0.005)
and women (regression coefﬁcient =
20.51% per year, SE = 0.23, Plinear trend =
0.028)(Table1).Thetestforaninteraction
between sex and study cycle was not sig-
niﬁcant (P =0 . 6 5 2 ) .S i g n i ﬁcant decreases
i nt h er i s kf o rC H Dw e r en o t e da m o n g
whites (regression coefﬁcient = 20.60%
peryear,SE= 0.19,P
linear trend0.002),African
Americans (regression coefﬁcient =
20.50% per year, SE = 0.10, Plinear trend
,0.001), and Mexican Americans (regres-
sion coefﬁcient = 20.50% per year, SE =
0.23, Plinear trend = 0.031) (Fig. 1). The
regression coefﬁcients of the three groups
did not differ statistically (P =0 . 9 1 5 ) .
Although the 10-year risk for CHD,
calculated using the ARIC study and FHS
risk equations, also decreased signiﬁ-
cantly among all participants, there was
some inconsistency among the risk equa-
tions regarding the signiﬁcance of trends
stratiﬁed by race or ethnicity (Fig. 1). The
UKPDS risk estimates showed signiﬁcant
decreases among all three major racial or
ethnicgroups(Plinear trend:whites=0.002;
African Americans ,0.001; and Mexican
Americans = 0.031), the ARIC study risk
estimates indicated signiﬁcant reductions
among whites and Mexican Americans
Figure 1—Estimated 10-year risk (95% CI) for developing CHD among adults with diagnosed
diabetesintheU.S.byraceorethnicity(NHANES).A:UKPDSriskestimatesamongparticipants
aged 30–79 years. B: ARIC study risk estimates among participants aged 45–65 years. C:F H S
risk estimates among participants aged 30–74 years.
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Trends in CVD risk among diabetic adultsbut not among African Americans (Plinear
trend: whites = 0.006; African Americans =
0.274; and Mexican Americans = 0.014),
andthe FHSrisk estimatesshowed signif-
icant decreases among whites and African
Americans (Plinear trend: whites = 0.001;
African Americans = 0.033; and Mexican
Americans = 0.065).
Calculations of hypothetical reduc-
tions in 10-year UKPDS risk suggested
that improving the ratio of TC/HDLC
could result in the largest reduction in
riskforCHD(Table2).Theapplicationof
simultaneous modiﬁcations of all four
risk factors to the 2007–2008 data sug-
gested that the estimated risk for CHD
(11.4%) could have been ~30% lower
than the actual estimates (16.4%).
CONCLUSIONS—Compared with
1999–2000, the estimated 10-year UKPDS
risk for developing CHD among people
with diagnosed diabetes was 22% lower
by 2007–2008. The estimated risk for
CHD decreased signiﬁcantly among men,
women, whites, African Americans, and
Mexican Americans. Improvements in
concentrations of HbA1c, systolic blood
pressure, and the ratio of TC/HDLC
mostly accounted for the decreased risk.
The mortality rate of CHD in the U.S.
population has decreased tremendously
sincethe1960s(9).Medicaltreatmentsof
CHD and favorable trends in key risk fac-
tors for CHD have contributed roughly
equally to this decline (10). Whether the
incidence of CHD also demonstrated fa-
vorable secular trends has been less clear.
Although trends in the incidence of CHD
among people with diabetes remain un-
known, people with diabetes have expe-
rienced decreases in the mortality rate
from cardiovascular disease (11–13).
One study (12) showed that the mortality
rate from cardiovascular disease de-
creased substantially among men but
decreased little among women with dia-
betes. In the FHS, however, men and
women experienced similar reductions
in mortality from cardiovascular disease
(13). The results of the current study
showed that risk declined signiﬁcantly
to a similar extent among both men and
women. Because the UKPDS risk engine
used fatal and nonfatal myocardial infarc-
tion or sudden death as its end point, it is
possible that changes in mortality be-
tween men and women could differ
even if changes in incidence were similar
because of differences in the case-fatality
rate. Therefore, surveillance for the inci-
dence of cardiovascular disease and the
case-fatality rate among people with dia-
betes is of critical importance to under-
standing the dynamics of this diabetes
complication.
The difference in estimated UKPDS
risk between men and women is partially
afunctionoftheUKPDSriskequationbe-
cause the sex coefﬁcient assigns a lower
risk to women. The difference in the
estimated risk for CHD among the three
major racial or ethnic groups can be
attributed to differences in the coefﬁcient
for race or ethnicity in the UKPDS risk
engine as well as to the more favorable
lipid proﬁle in African Americans than
the other groups because the UKPDS risk
engine assigns a great deal of weight to
the coefﬁcient for the ratio of TC/HDLC.
The coefﬁcient for the race or ethnicity
variable in the ARIC study risk equations
also indicates a lower risk for African
Americans. Thus, both the UKPDS and
ARICstudyriskequationspredictthatthe
risk for developing CHD is lower among
African Americans than whites when val-
ues for the risk factors are the same.
The UKPDS and FHS risk estimates
suggested that favorable developments in
the risk for developing CHD extended to
all three major racial or ethnic groups.
The estimated UKPDS risk during 2007–
2008 was 43% lower among African
Americans, 22% lower among Mexican
Americans, and 20% lower among whites
compared with 1999–2000. However,
the ARIC study risk estimates did not
show a signiﬁcant decrease in the risk
for CHD among African Americans,
and the FHS risk estimates for Mexican
A m e r i c a n ss h o w e dar e d u c t i o ni nr i s k
over time that was of borderline signiﬁ-
cance.Becauseanalysesstratiﬁedbyrace
or ethnicity failed to demonstrate signif-
icant reductions in several risk factors,
reducing smoking, HbA1c, and blood
pressure among whites; smoking among
African Americans; and blood pressure
and TC among Mexican Americans is
critical to further reducing the future
risk for CHD in these groups.
Population studies in the U.S. have
shown increased treatment for and con-
trol of hypercholesterolemia and hyper-
tension (3,14). Increased uptake of
medications to lower blood glucose, sys-
tolic blood pressure, and TC by people
withdiabeteslikelycontributedtotheim-
provements in these risk factors (4). Less
clearistheroleoflifestylebehaviors,such
as physical activity and diet (saturated fat,
polyunsaturated fat, trans fats, dietary
cholesterol, salt, and fruits and vegeta-
bles), in affecting the observed trends. Al-
though an anthropometric measure is not
part of any of the three risk engines used
in the current study, excess weight pro-
motes increased blood pressure and
dyslipidemias. Thus, weight manage-
ment is critical to optimizing levels of
blood pressure and lipids that are
Table 2—Estimated UKPDS 10-year risk for CHD among adults with diagnosed diabetes,
aged 30–79 years, in the U.S. under different scenarios by study period, NHANES
1999–2008
Reduction scenario
1999–2000 2001–2002 2003–2004 2005–2006 2007–2008
Percentage
or mean
(SE)†
Percentage
or mean
(SE)†
Percentage
or mean
(SE)†
Percentage
or mean
(SE)†
Percentage or
mean
(SE)†
n* 335 338 363 374 567
UKPDS 10-year risk 21.1 (1.4) 17.6 (0.7) 19.0 (1.1) 13.8 (0.9) 16.4 (0.8)
UKPDS 10-year risk,
eliminate smoking 20.3 (1.3) 16.9 (0.8) 18.0 (1.1) 13.3 (0.9) 15.8 (0.8)
UKPDS 10-year risk,
HbA1c ,7% 18.5 (1.3) 15.5 (0.7) 17.3 (1.0) 12.8 (0.9) 15.0 (0.7)
UKPDS 10-year risk,
systolic blood pressure
,130 mmHg 19.7 (1.3) 16.7 (0.7) 17.9 (1.1) 12.9 (0.8) 15.5 (0.7)
UKPDS 10-year risk,
decrease ratio of
TC/HDLC 17.2 (1.2) 14.4 (0.5) 16.0 (0.9) 11.9 (0.8) 13.8 (0.7)
UKPDS 10-year risk,
implement all 13.4 (1.0) 11.4 (0.6) 13.2 (0.8) 10.0 (0.7) 11.4 (0.6)
*Unweighted sample size. †Estimates calculated using sampling weights.
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Fordimportant components of the UKPDS
risk engine and to estimating cardiovas-
cular risk.
The present analysis suggests that
reducing TC to ,200 mg/dL and raising
HDLC to at least 40 mg/dL in men and 50
mg/dL in women would result in the larg-
est reduction in risk. In part, the size of
the potential risk reduction was governed
bythehighprevalenceofdyslipidemiasof
69.5%. Optimizing medical management
and promoting behavioral change, such
as increasing physical activity (keeping
in mind medical limitations), improving
dietary quality, and weight management,
cancontributetoloweringconcentrations
of HbA1c, blood pressure, and concentra-
tions of lipids. Smoking is an important
risk factor for CHD. Therefore, the ab-
sence of a meaningful decrease in the
prevalence of smoking in diabetic adults
during the 10-year study period suggests
that this behavior contributed little to the
observed trends in the estimated risk for
CHD. Had all diabetic participants who
werecurrentsmokersnotsmoked,thees-
timated risk would have been ~4% lower
in 1999–2000 and in 2007–2008.
Clinical trials, especially the more
recent ones, have generated considerable
controversy concerning the effect of gly-
cemic control, particularly rigorous gly-
cemiccontrol,onall-causemortality(15).
Therefore, the hypothetical reductions in
riskforCHDattributabletoglycemiccon-
trol discussed above should be viewed
with considerable caution. Meta-analyses
of clinical trials in people with diabetes
demonstrated that treating patients with
hypertension or elevated concentrations
ofLDLcholesterolimprovescardiovascu-
lar outcomes (16,17), and, therefore, the
control of these two risk factors is clearly
vitalinreducingtheriskforCHDinpeople
with diabetes. Furthermore, comprehen-
sive management of major cardiovascular
risk factors in people with diabetes greatly
reduces cardiovascular disease (18).
The number of risk prediction algo-
rithms to calculate the risk for CHD or
cardiovascular disease has increased sub-
stantially since the emergence of risk
prediction for CHD. Because the FHS
and other risk prediction algorithms
may not adequately assess the risk for
CHD among people with diabetes (19),
twoadditionalriskpredictionalgorithms,
the UKPDS and ARIC study risk predic-
tion algorithms that were developed us-
ing samples of diabetic participants, were
used in the current study. The UKPDS
risk prediction algorithm, however, was
developed using data from a cohort of
participants with diabetes who did not
havearecenthistoryofmyocardialinfarc-
tion, angina, or heart failure. Thus, this
risk prediction algorithm may underesti-
matetheriskfordevelopingCHDinstud-
ies, such as the present one that include
participants with such histories of myo-
cardial infarction, angina, or heart failure.
The predictive ability of several risk pre-
diction algorithmsamong people with di-
abetes has been compared with observed
outcomes in a number of prospective
studies (19–24). The FHS risk prediction
algorithm underestimated the observed
risk for CHD in some studies (19,21)
and overestimated the risk in others
(22–24). The UKPDS risk prediction al-
gorithm also overestimated the risk in
some studies (21–24). A comparison of
risk functions in New Zealand showed
that the 5-year UKPDS risk estimates
were lower than the FHS risk estimates
(25). Thus, considerable uncertainty ex-
ists about how best to estimate the risk
for cardiovascular disease in people with
diabetes.
Several limitations deserve mention.
First, diagnosed diabetes was based on
self-reported information and is thus
subject to some degree of erroneous re-
porting and misclassiﬁcation. However,
self-reported diabetes generally has good
sensitivity and speciﬁcity. Second, the
number of participants with diagnosed
diabetes was too small to calculate rea-
sonably stable estimates of risk for CHD
by several levels of stratiﬁcation of the
study variables. Third, estimates of 10-
year risk were calculated for the three
majorracialorethnicgroups.TheUKPDS
and ARIC study participants included
participants of African heritage, and,
therefore, the use of these two sets of
risk equations among African Americans
in the current study appears reasonable,
although limited experience exists con-
cerning the use of these risk equations in
African American populations. Further-
more, the validity of applying these equa-
tions to samples of participants of
Hispanic heritage remains to be estab-
lished. Furthermore, estimates for only
three major racial or ethnic groups were
calculated because data for other races or
ethnicities were not available or had in-
adequate sample size. Thus, studies fo-
cused on other races or ethnicities will be
helpful to examine the totality of the
dynamics of CHD among people with
diabetes. Finally, the laboratories and
methods for measuring HbA1c and lipids
changed during the 10-year period.
Crossover studies were performed to
examine the possible effects of these
changes, and equations were developed
to bridge any differences. The changes
in the methodology for measuring con-
centrations of HDLC may have partially
led to the increase in the means of
HDLC from 1999 to 2006, particularly
after all specimens were analyzed by using
the direct method of measuring HDLC
starting in 2003. Therefore, it is possible
that this artifact may have been responsi-
bleforsomesmallproportionofthefavor-
able trend in the risk for CHD that was
observed.
Inconclusion,recentfavorabletrends
in several major risk factors for CHD,
namely HbA1c, systolic blood pressure,
and the ratio of TC/HDLC, have resulted
in an encouraging reduction in the esti-
mated risk for CHD among adults with
diagnosed diabetes in the U.S. The esti-
mates from the current study also suggest
that continuing declines in the mortality
rate from CHD among people with diabe-
tes can be anticipated going forward. Sus-
tained efforts in targeting these three risk
factors as well as an additional focus on
reducing smoking in the diabetic popula-
tion should further beneﬁtt h ec a r d i o v a s -
cular health of people with diabetes.
Because the most recent data did not in-
dicate that the decrease in the estimated
risk for CHD from 1999–2000 to 2005–
2006 continued into 2007–2008, future
monitoring will be essential to determine
whether this possible interruption in the
trend is a temporary phenomenon that
may represent sampling variation or
represents a real change in the direction
of the trend.
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